Key clinical point: Patients with prostate cancer who receive second-generation antiandrogens show higher risk for depression vs those who receive traditional hormone therapy (HT) alone or no HT.
Major finding: Second-generation antiandrogens were associated with increased risk for depression vs no HT (hazard ratio [HR], 2.15; P < .001). The risk for depression with second-generation antiandrogens was also higher vs traditional HT (HR, 2.26; P < .001), including specifically among those with metastatic disease at diagnosis (HR, 2.40; P = .002).
Study details: A retrospective study of 30,069 patients with prostate cancer without a second cancer over the course of 12 months between 2011 and 2015.
Disclosures: This work is supported by National Institutes of Health, Cancer Prevention and Research Institute of Texas, and Susan G. Komen for the Cure. The authors did not report any conflict of interests.
Source: Nowakowska MK et al. JAMA Netw Open. 2021 Dec 23. doi: 10.1001/jamanetworkopen.2021.40803 .